Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125419541 | 12541954 | 1 | I | 20160630 | 20160708 | 20160708 | EXP | GB-MHRA-EYC 00141608 | GB-MYLANLABS-2016M1027973 | MYLAN | 0.00 | Y | 0.00000 | 20160708 | PH | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125419541 | 12541954 | 1 | PS | INDAPAMIDE. | INDAPAMIDE | 1 | Oral | 2.5 MG, QD | Y | U | 74461 | 2.5 | MG | QD | |||||
| 125419541 | 12541954 | 2 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MG, QD | Y | U | 0 | 20 | MG | QD | |||||
| 125419541 | 12541954 | 3 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | UNK | U | 0 | ||||||||||
| 125419541 | 12541954 | 4 | C | QUININE | QUININE | 1 | UNK | U | 0 | ||||||||||
| 125419541 | 12541954 | 5 | C | SIMVASTATIN. | SIMVASTATIN | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125419541 | 12541954 | 1 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125419541 | 12541954 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125419541 | 12541954 | Circulatory collapse | |
| 125419541 | 12541954 | Hypomagnesaemia | |
| 125419541 | 12541954 | Hyponatraemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |